My watch list
my.bionity.com  
Login  

44 Current news about the topic protease inhibitors

rss

You can refine your search further. Select from the filter options on the left to narrow down your results.

image description
A new way to nip AIDS in the bud

Protease might become a friend instead of foe in fighting HIV

14-Jun-2016

When new AIDS virus particles bud from an infected cell, an enzyme named protease activates to help the viruses mature and infect more cells. That's why modern AIDS drugs control the disease by inhibiting protease. Now, University of Utah researchers found a way to turn protease into a ...

more

Advises on compassionate use of a new combination therapy for chronic hepatitis C

Combination of ledipasvir and sofosbuvir to be used in patients in urgent need of therapy to prevent progression of liver disease

26-Feb-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has given an opinion on the use of a fixed-dose combination of ledipasvir and sofosbuvir in the treatment of chronic (long-term) hepatitis C virus (HCV) infection in a compassionate-use ...

more

European Medicines Agency advises on compassionate use of daclatasvir

Opinion concerns use in combination with sofosbuvir in patients with chronic hepatitis C in urgent need of therapy to prevent progression of liver disease

03-Dec-2013

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has given an opinion on the use of daclatasvir in combination with sofosbuvir in the treatment of chronic (long-term) hepatitis C virus (HCV) infection, in a compassionate-use programme. Compassionate-use ...

more

Frost & Sullivan: Combination drugs are the future of the European Hepatitis B and C therapeutics markets

02-May-2013

The limited efficacy and negative side-effects associated with current therapeutics for Hepatitis B and C are highlighting the urgent need for new, improved alternatives. Combination therapies offering better clinical outcomes are coming to the fore and look set to transform the European market ...

more

Medivir announces a phase II all-oral study of Simeprevir (TMC435) and VX-135 for the treatment of Hepatitis C to be conducted by Janssen and Vertex

07-Nov-2012

Medivir AB announced plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen’s protease inhibitor simeprevir and Vertex’s nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135. Janssen will conduct a ...

more

Medivir's TMC435 will be evaluated in a phase II combination study with daclatasvir (BMS 790052) for HCV genotype-1 patients

07-Dec-2011

Medivir AB announced that its development partner, Tibotec Pharmaceuticals, has entered into an agreement with Bristol-Myers Squibb Company. TMC435, a once daily NS3/4A protease inhibitor (PI) for the treatment of genotype-1 chronic hepatitis C virus (HCV) infection will be investigated in ...

more

Medivir's TMC649128 enters Phase Ib Trial in Patients Chronically Infected with Genotype-1 Hepatitis C Virus

24-Jun-2011

Medivir AB announced the start of a phase Ib clinical trial with TMC649128 intended for the treatment of chronic hepatitis C virus (HCV) infection.TMC649128 is a nucleoside NS5B polymerase inhibitor developed in collaboration with Tibotec Pharmaceuticals. TMC649128 has demonstrated an ...

more

Putting the Brakes on Drug-Resistant HIV

Probing Multidrug Resistance and Protein-Ligand Interactions with Oxatricyclic Designed Ligands in HIV-1 Protease Inhibitors

22-Sep-2010

HIV-1 protease inhibitors were added as a component of highly active antiretroviral therapy (HAART) in the mid-1990s, and have played a key role in that treatment regimen ever since. However, the emergence of multidrug-resistant HIV strains requires the discovery and design of conceptually new ...

more

Genetic Technologies appoints Lewis J. Stuart as General Manager of its New North American Molecular Diagnostics Business

23-Jun-2010

Genetic Technologies Limited announced the appointment of Mr. Lewis Stuart as General Manager of its North American molecular diagnostics business. The new division is the result of the Company’s recent acquisition of US assets including BREVAGen™, a fully validated risk assessment test for ...

more

Idenix Pharmaceuticals Initiates Proof-of-Concept Study for Protease Inhibitor IDX320 in Hepatitis C Patients

14-Jun-2010

Idenix Pharmaceuticals, Inc. announced that it has initiated a 3-day proof-of-concept study of IDX320, a protease inhibitor for the treatment of hepatitis C virus (HCV) infection, under a Clinical Trial Application (CTA). The study is evaluating IDX320 in treatment-naive hepatitis C genotype ...

more

Page 1 From 5
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE